Posted by Michael Wonder on 05 Jun 2024
Ivosidenib in combination with azacitidine for the first-line treatment of patients with IDH1 R132 mutation positive acute myeloid leukaemia (final guidance)
5 June 2024 - NICE has published final evidence-based guidance on the use of ivosidenib with azacitidine in the NHS in England.
The combination of ivosidenib and azacitidine is now recommended for the treatment of adults with newly diagnosed acute myeloid leukaemia with an IDH1 R132 mutation who cannot have standard intensive induction chemotherapy.
